Obecabtagene Autoleucel
Phase 2Cell therapy
This medication is a type of immunotherapy made from a patient's own immune cells that has been specially engineered to recognize and attack acute lymphoblastic leukemia cancer cells. It is used to treat adults with this type of blood cancer when it has returned or stopped responding to other treatments.[1] Obecabtagene Autoleucel is currently being investigated across 5 indications[3], with its most advanced program in Phase 2.[1]
Obecabtagene Autoleucel is one of 157 small molecule programs targeting Lupus Nephritis. It is currently in Phase 2.
5
Indications
5
Total Trials
5
Active Trials
156
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
163 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Oncaspar
SServier
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Fludara
SanofiPhase 3
Iclusig
TakedaPhase 3
Cellcept
RochePhase 3
Neoral
NovartisPhase 3
Arranon
NovartisPhase 3
Jakafi
IncytePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lupus Nephritis1 trial
Acute Lymphoblastic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Obecabtagene Autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- AAutolus Limited